CJC-1295 (DAC): How the DAC Tag Stretches GH Release to Days

CJC-1295 Overview & Molecular Profile

MECHANISM OF ACTION

CJC-1295 is a synthetic GHRH analog built on the first 29 amino acids of GHRH with a Drug Affinity Complex (DAC) lysine modification that enables covalent binding to serum albumin. This albumin binding extends the half-life from minutes to 6–8 days, enabling once-weekly dosing with sustained GH and IGF-1 elevation. First described in a 2006 JCEM study, it exists in two forms: with DAC (long-acting) and without DAC (Modified GRF 1-29; ~30-minute half-life).

Mechanism of Action: Hormonal Signaling & Receptor Binding

MOLECULAR STRUCTURE

CJC-1295 acts on the GHRH receptor in the pituitary gland to stimulate growth hormone release. The DAC modification allows the peptide to bind covalently to serum albumin after injection, protecting it from enzymatic degradation and extending its biological half-life from minutes to days. This results in sustained elevation of GH and IGF-1 levels. The peptide amplifies the natural GH pulsatile release pattern rather than creating artificial spikes.

Drug Affinity Complex: Engineering a 6-8 Day GHRH Analog

CJC-1295 represents a unique approach to peptide half-life extension: covalent albumin conjugation via a Drug Affinity Complex (DAC). Unlike the reversible albumin binding used by GLP-1 agonists, the DAC forms an irreversible bond with serum albumin, creating a circulating depot that extends the half-life of a GHRH analog from minutes to days.

The DAC Covalent Albumin-Binding Mechanism

The Drug Affinity Complex technology was specifically developed to overcome the rapid degradation of GHRH analogs, which have half-lives measured in minutes without modification. • A maleimidopropionyl-lysine linker reacts with Cys34 on serum albumin after subcutaneous injection, forming an irreversible thioether covalent bond. This conjugation extends the half-life from approximately 30 minutes (for unmodified Mod GRF 1-29) to 6-8 days. • A single subcutaneous dose produces dose-dependent GH elevation sustained over the full 6-8 day half-life period, with IGF-1 elevation persisting up to 14 days (approximately 2x baseline). • Without DAC (marketed as Mod GRF 1-29 or Modified GRF), the peptide retains the same GHRH receptor agonist activity but requires 2-3 daily administrations due to the ~30-minute half-life.

Pulsatile GH Amplification, Not Constant Elevation

A critical distinction in CJC-1295's pharmacodynamics is that it amplifies the body's natural pulsatile GH secretion rather than creating a constant, non-physiologic GH level. • CJC-1295 enhances the amplitude of endogenous GH pulses — each natural GH secretory episode is amplified by the persistent GHRH receptor stimulation, rather than being replaced by a flat, elevated GH concentration. • This preservation of pulsatility distinguishes CJC-1295 from exogenous GH administration, which suppresses endogenous GH pulsatility through negative feedback. • The combination of CJC-1295 (GHRH analog) with a GHRP such as Ipamorelin (GHSR-1a agonist) produces synergistic GH release — the two receptor pathways converge on the somatotroph to produce GH secretion greater than either agent alone.

Sustained GH Elevation

Research demonstrates that CJC-1295 with DAC produces remarkably prolonged elevation of growth hormone levels lasting 6-8 days following a single subcutaneous injection, fundamentally different from the short-lived pulses produced by other GH-releasing compounds. The Drug Affinity Complex binds covalently to albumin in the bloodstream, protecting the peptide from enzymatic degradation and extending its biological activity dramatically. Studies show 2-10 fold elevations in mean GH levels that persist throughout the week, while importantly maintaining the natural pulsatile secretion pattern rather than creating unnatural constant elevation. This sustained release profile has made CJC-1295 valuable for research into growth hormone replacement strategies, aging-related GH decline, and optimization of GH therapy protocols. The extended half-life also enables study of long-term GH elevation effects without the confounding variable of repeated daily injections.

Research Protocol Doses Reported in Published Literature

Research Disclaimer: Doses reported below are from published preclinical research protocols. CJC-1295 is not approved for human use by the FDA or any regulatory agency. This information is provided for research reference only and does not constitute a dosing recommendation. All doses above are reported from published research protocols using laboratory subjects. Refer to the cited studies in the Research Studies section above for original source data.

Safety & Tolerability

In the one published human clinical study of CJC-1295 with DAC — a Phase I dose-escalation trial in healthy adults — tolerability was characterized as good, with injection-site reactions reported as the most common adverse effect. No quantitative human safety data beyond this exists, and long-term safety is uncharacterized. Human data: Human evidence is limited to a single published Phase I/II pharmacokinetic-pharmacodynamic dose-escalation study in healthy adults; no efficacy trials, long-term safety studies, or regulatory review have followed. Sustained GHRH-receptor stimulation raises a theoretical concern about pituitary desensitization or feedback suppression, which the published study noted but did not observe within its window. Regulatory status: Not approved for any medical use by any regulatory agency; available only as a research compound. In the published Phase I dose-escalation study in healthy adults, CJC-1295 with DAC showed good tolerability, with injection-site reactions reported as the most common adverse effect. Human PK In the published Phase I dose-escalation study in healthy adults, CJC-1295 with DAC showed good tolerability, with injection-site reactions reported as the most common adverse effect. Sustained GHRH-receptor activation could theoretically cause receptor downregulation or feedback suppression of endogenous GH secretion; the 2006 clinical study noted this concern but did not observe pituitary desensitization within its study window. Human PK Sustained GHRH-receptor activation could theoretically cause receptor downregulation or feedback suppression of endogenous GH secretion; the 2006 clinical study noted this concern but did not observe pituitary desensitization within its study window.

Key Findings at a Glance

• The Drug Affinity Complex modification allows CJC-1295 to covalently bond to serum albumin after injection, extending its half-life from minutes to 6 to 8 days. • A single injection of CJC-1295 with DAC can elevate IGF-1 levels for up to two weeks, a duration unmatched by any other GHRH analog studied in clinical settings. • CJC-1295 combined with a GHRP such as Ipamorelin or GHRP-6 produces 2 to 5 times more growth hormone than either peptide alone, due to activation of complementary pituitary pathways. • CJC-1295 exists in two distinct forms with vastly different pharmacokinetics: the DAC version acts for days, while Modified GRF 1-29 without DAC has a half-life of only 30 minutes.

Body Composition Research

Research indicates CJC-1295 may influence body composition through multiple GH and IGF-1 mediated pathways including enhanced lipolysis (fat breakdown), increased lean body mass, and improved protein synthesis in skeletal muscle tissue. Studies have documented potential reductions in visceral adipose tissue (abdominal fat), which is associated with metabolic disease risk, along with improvements in fat-free mass. The peptide has been investigated for obesity research applications, sarcopenia (age-related muscle loss) prevention studies, and metabolic syndrome investigations. Long-term animal studies suggest favorable body composition changes including reduced body fat percentage and increased muscle mass without the water retention sometimes associated with direct GH administration. These findings have implications for research into healthy aging, athletic performance optimization, and metabolic health.

Sleep Quality Studies

Preliminary research suggests CJC-1295 may improve sleep architecture, particularly enhancing slow-wave (deep) sleep phases when natural growth hormone release peaks occur. Studies indicate that optimized GH pulsatility achieved through GHRH analog administration may support the natural relationship between deep sleep and growth hormone secretion. Research has documented improvements in subjective sleep quality measures and potential enhancement of recovery processes associated with quality sleep. These findings have implications for aging research where both sleep quality and GH production naturally decline, as well as for recovery optimization studies in athletic and rehabilitation contexts. The sustained GH elevation may support overnight recovery and tissue repair processes.

Synergistic GHRP Combination

Extensive research demonstrates that CJC-1295 produces synergistic effects when combined with growth hormone releasing peptides such as Ipamorelin or GHRP-6, resulting in substantially greater GH release than either compound alone. This synergy occurs because CJC-1295 acts on GHRH receptors while GHRPs act on ghrelin receptors, activating complementary pathways that amplify pituitary GH secretion. Studies document 2-5 fold greater GH release with combined administration compared to either peptide individually. This combination approach has become a standard research protocol for studying maximized natural GH secretion, optimal body composition effects, and the potential therapeutic applications of enhanced GH/IGF-1 axis activation.

Half-Life & Dosing Cadence

CJC-1295 (DAC) has a reported elimination half-life of ~6-8 days. The half-life is the time it takes for blood levels to fall by half, and it's the single biggest driver of how often you dose. That's why the typical schedule lands around 1-2x weekly at 1–2 mg — frequent enough to keep levels in a useful range without stacking up. Shorter half-lives mean more frequent dosing and faster clearance if you stop; longer ones mean steadier levels but a slower washout.

Administration & Absorption

CJC-1295 (DAC) is administered by subcutaneous injection (into the fat layer just under the skin). The primary route is subcutaneous. Subcutaneous delivery is absorbed steadily from the fat depot, giving smoother peaks than intramuscular dosing. Whichever route you use, rotate sites and follow sterile technique.

Reconstitution & Handling

CJC-1295 (DAC) ships as a lyophilized (freeze-dried) powder that you reconstitute before use — a common starting point is a 2 mg vial with 2 mL of bacteriostatic water. Add the water slowly down the vial wall, swirl (don't shake), and let it fully dissolve. Reconstituted peptide is refrigerated and used within its stability window; unmixed powder keeps far longer when stored cold and dark. Always confirm exact dosing math against your own vial and concentration.

Onset & Clearance

Because of its ~6-8 days half-life, CJC-1295 (DAC) reaches steady levels after a few consistent doses and clears the system within roughly four to five half-lives once you stop. Track how you respond over a defined block rather than judging any single dose, and give the compound enough consistent days before deciding whether it's working. This is educational information, not medical advice — review your protocol with a clinician.